PLACEBO for GIVINOSTAT hydrochloride monohydrate (ITF2357) 10 mg/mL oral suspension, ITF2357
DSC/14/2357/50
Phase 3 small_molecule active
Quick answer
PLACEBO for GIVINOSTAT hydrochloride monohydrate (ITF2357) 10 mg/mL oral suspension, ITF2357 for Duchenne muscular dystrophy (DMD) is a Phase 3 program (small_molecule) at Italfarmaco S.p.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Italfarmaco S.p.A.
- Indication
- Duchenne muscular dystrophy (DMD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active